Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain

Therapeutic Drug Monitoring

Volumn 36, Issue 3, 2014, Pages 335-344

  De Gregori, Simona ^a   Minella, Cristina E ^a,b   De Gregori, Manuela ^a,b   Tinelli, Carmine ^c   Ranzani, Guglielmina N ^a,d   Govoni, Stefano ^a,e   Allegri, Massimo ^a,b   Regazzi, Mario ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b Fondazione IRCCS Policlinico S Matteo: Pain Therapy Service   (United States)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d Microbiology II: Department of Experimental and Applied Pharmacology   (Italy)

^e Drug Sciences   (Italy)

Author keywords

cancer; chronic pain; dose titration; morphine; Pharmacokinetics; therapeutic drug monitoring

Indexed keywords

MORPHINE 3 GLUCURONIDE; MORPHINE SULFATE; MORPHINE; MORPHINE DERIVATIVE; MORPHINE-3-GLUCURONIDE; MORPHINE-6-GLUCURONIDE; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; ANALGESIA; AREA UNDER THE CURVE; ARTICLE; CANCER PAIN; CLINICAL ARTICLE; CORRELATION ANALYSIS; DIZZINESS; DROWSINESS; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; FOLLOW UP; GENE LINKAGE DISEQUILIBRIUM; HAPLOTYPE; HUMAN; HUMAN TISSUE; MALE; NAUSEA; PHARMACOGENETICS; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT WITHDRAWAL; AGE; BODY MASS; CHRONIC PAIN; CLINICAL TRIAL; COMPLICATION; DRUG MONITORING; GENETIC POLYMORPHISM; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; NEOPLASM; PAIN MEASUREMENT; SEX DIFFERENCE; TANDEM MASS SPECTROMETRY; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; BODY MASS INDEX; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHRONIC PAIN; DRUG MONITORING; FEMALE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MORPHINE; MORPHINE DERIVATIVES; NEOPLASMS; PAIN MEASUREMENT; POLYMORPHISM, GENETIC; SEX FACTORS; TANDEM MASS SPECTROMETRY;

EID: 84901418744     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000009     Document Type: Article

References (38)

1. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18:1437-1449.
2. Deandrea S, Montanari M, Moja L, et al. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol. 2008;19: 1985-1991.
3. Caraceni A, Hanks G, Kaasa S, et al; European Palliative Care Research Collaborative (EPCRC); European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012; 13:e58-e68.
4. De Gregori M, De Gregori S, Ranzani GN, et al. Individualizing pain therapy with opioids: the rational approach based on pharmacogenetics and pharmacokinetics. Eur J Pain Suppl. 2010;4:245-250.
5. Fainsinger RL, Nekolaichuk C, Lawlor P, et al. An international multicentre validation study of a pain classification system for cancer patients. Eur J Cancer. 2010;46:2896-2904.
6. Hanks GW, Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001;84:587-593.
7. Diatchenko L, Slade GD, Nackley AG, et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet. 2005;14:135-143.
8. Duguay Y, Br C, Skorpen F, et al. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther. 2004;75:223-233.
9. Holthe M, Klepstad P, Zahlsen K, et al. Morphine glucuronide-tomorphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur J Clin Pharmacol. 2002;58:353-356.
10. Oertel BG, Kettner M, Scholich K, et al. A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J Biol Chem. 2009;284:6530-6535.
11. Wilson JF. The pain divide between men and women. Ann Intern Med. 2006;144:461-464.
12. Fondazione IRCCS Policlinico S. Matteo, Pavia, and University of Pavia, Italy. Prospective Study About Clinical and Pharmacogenetic Safety of Opioid Use for Chronic Pain. ClinicalTrials.gov Identifier: NCT00916890. Protocol Registration Receipt 10/21/2010.
13. von Elm E, Altman DG, Egger M, et al; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453-1457.
14. Ladd LA, Kam PC, Williams DB, et al. Ventilatory responses of healthy subjects to intravenous combinations of morphine and oxycodone under imposed hypercapnic and hypoxaemic conditions. Br J Clin Pharmacol. 2005;59:524-535.
15. Gomeni R, Pineau G, Mentr F. Population kinetics and conditional assessment of the optimal dosage regimen using the P-PHARM software package. Anticancer Res. 1994;14:2321-2326.
16. Mentre- F, Gomeni R. A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics. J Biopharm Stat. 1995;5:141-158.
17. Nordberg G, Borg L, Hedner T, et al. CSF and plasma pharmacokinetics of intramuscular morphine. Eur J Clin Pharmacol. 1985;27: 677-681.
18. Samuelsson H, Nordberg G, Hedner T, et al. CSF and plasma morphine concentrations in cancer patients during chronic epidural morphine therapy and its relation to pain relief. Pain. 1987;30:303-310.
19. Swe J, Svensson JO, Rane A. Morphine metabolism in cancer patients on increasing oral doses-no evidence for autoinduction or dosedependence. Br J Clin Pharmacol. 1983;16:85-93.
20. Vater M, Smith G, Aherne GW, et al. Pharmacokinetics and analgesic effect of slow-release oral morphine sulphate in volunteers. Br J Anaesth. 1984;56:821-827.
21. Bowsher D. Pain syndromes and their treatment. Curr Opin Neurol Neurosurg. 1993;6:257-263.
22. Faura CC, Collins SL, Moore RA, et al. Systematic review of factors affecting the ratios of morphine and its major metabolites. Pain. 1998;74:43-53.
23. Faura CC, Moore RA, Horga JF, et al. Morphine and morphine-6-glucuronide plasma concentrations and effect in cancer pain. J Pain Symptom Manage. 1996;11:95-102.
24. McQuay HJ, Carroll D, Faura CC, et al. Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin Pharmacol Ther. 1990;48:236-244.
25. Yue Q, von Bahr C, Odar-Cederlf I, et al. Glucuronidation of codeine and morphine in human liver and kidney microsomes: effect of inhibitors. Pharmacol Toxicol. 1990;66:221-226.
26. Bowsher D. Paradoxical pain. When the metabolites of morphine are in the wrong ratio. BMJ. 1993;306:473-474.
27. Portenoy RK, Foley KM, Stulman J, et al. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure. Pain. 1991;47:13-19.
28. Sjgren P, Thunedborg LP, Christrup L, et al. Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration Six case histories. Acta Anaesthesiol Scand. 1998;42:1070-1075.
29. Aubrun F, Langeron O, Quesnel C, et al. Relationships between measurement of pain using visual analog score and morphine requirements during postoperative intravenous morphine titration. Anesthesiology. 2003;98:1415-1421.
30. Mazoit JX, Butscher K, Samii K. Morphine in postoperative patients: pharmacokinetics and pharmacodynamics of metabolites. Anesth Analg. 2007;105:70-78.
31. Hanks GW, Reid C. Contribution to variability in response to opioids. Support Care Cancer. 2005;13:145-152.
32. Kowarik MC, Einhuser J, Jochim B, et al. Impact of the COMT Val(108/158)Met polymorphism on the mu-opioid receptor system in the human brain: mu-opioid receptor, met-enkephalin and beta-endorphin expression. Neurosci Lett. 2012;506:214-219.
33. Ross J, Riley J, Taegetmeyer A, et al. Genetic variation and response to morphine in cancer patients. Cancer. 2008;112:1390-1403.
34. Skorpen F, Laugsand EA, Klepstad P, et al. Variable response to opioid treatment: any genetic predictors within sight Palliat Med. 2008;22: 310-327.
35. Arnr S, Arnr B. Differential effects of epidural morphine in the treatment of cancer-related pain. Acta Anaesthesiol Scand. 1985;29:32-36.
36. Samuelsson H, Hedner T. Pain characterization in cancer patients and the analgetic response to epidural morphine. Pain. 1991;46:3-8.
37. Macintyre PE, Jarvis DA. Age is the best predictor of postoperative morphine requirements. Pain. 1996;64:357-364.
38. Aubrun F, Salvi N, Coriat P, et al. Sex-and age-related differences in morphine requirements for postoperative pain relief. Anesthesiology. 2005;103:156-160.